2011
DOI: 10.1002/dmrr.1275
|View full text |Cite
|
Sign up to set email alerts
|

1,25‐Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo

Abstract: We conclude that in vitro 1,25(OH)2D3 exposure alters dendritic cell behaviour, converting them into a cell type that drives T cells away from destruction towards a regulatory phenotype.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
66
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 91 publications
(69 citation statements)
references
References 48 publications
3
66
0
Order By: Relevance
“…However, clinical applications of DC-based therapies in autoimmune disease intervention are hampered by the concern that iDCs will develop into immunostimulatory cells upon encountering inflammatory stimuli in vivo. In this sense, we (9,14,18) and other investigators (6,7,12) showed that mDCs differentiated and matured in vitro in the presence of the biologically active form of vitamin D, 1,25(OH) 2 D 3 , produced a stable phenotype, typically characterized by low levels of Ag-presenting and costimulatory molecules (MHCII, CD80, CD86), as well as a high ratio of PD-L1/CD86 and anti-inflammatory cytokines (IL-10, TGF-b). In this study, we further demonstrated the capacity of 1,25(OH) 2 D 3 to imprint a similar tolerogenic profile in mDCs derived from diabetes-prone mice and diabetes-resistant animals.…”
Section: Discussionmentioning
confidence: 97%
See 2 more Smart Citations
“…However, clinical applications of DC-based therapies in autoimmune disease intervention are hampered by the concern that iDCs will develop into immunostimulatory cells upon encountering inflammatory stimuli in vivo. In this sense, we (9,14,18) and other investigators (6,7,12) showed that mDCs differentiated and matured in vitro in the presence of the biologically active form of vitamin D, 1,25(OH) 2 D 3 , produced a stable phenotype, typically characterized by low levels of Ag-presenting and costimulatory molecules (MHCII, CD80, CD86), as well as a high ratio of PD-L1/CD86 and anti-inflammatory cytokines (IL-10, TGF-b). In this study, we further demonstrated the capacity of 1,25(OH) 2 D 3 to imprint a similar tolerogenic profile in mDCs derived from diabetes-prone mice and diabetes-resistant animals.…”
Section: Discussionmentioning
confidence: 97%
“…BM-derived DCs were obtained in vitro, as previously described (18). Briefly, BM was isolated from long bones of C57BL/6 or NOD mice aged 4-5 wk.…”
Section: In Vitro Generation Of Bm-derived Murine Dcsmentioning
confidence: 99%
See 1 more Smart Citation
“…BMDCs were generated from 3 to 4 week-old mice according to a previously established protocol [6,18]. Briefly, bone marrow precursors were cultured in RPMI 1640 medium (Life Technologies, Rockville, MD, USA) supplemented with Glutamax-I, 25 mM HEPES, 10% heat-inactivated fetal calf serum (FCS) (Thermo Scientific, Sunnyvale, CA, USA), 50 mM 2-mecraptoethanol (2-ME) (UCB, Brussels, Belgium) and 100 U/ml Penicillin/Streptomycin in the presence of 20 ng/ml murine recombinant IL-4 and 20 ng/ml murine recombinant GM-CSF (Peprotech, Rocky Hill, NJ, USA) for 8 days.…”
Section: Generation Of Myeloid Dcsmentioning
confidence: 99%
“…granulocyte macrophage colony stimulating factor (GM-CSF)/interleukin (IL)-4 [myeloid or conventional DCs] and Flt-3 ligand [plasmacytoid DCs]). Upon binding of 1a,25(OH) 2 D 3 to the VDR, both the differentiation and maturation of particularly myeloid DCs will be inhibited, leading to reduced cell surface expression of CD40, CD80, and CD86 costimulatory molecules, reduced T cell stimulatory function, and decreased survival [6,7].…”
Section: Introductionmentioning
confidence: 99%